Published in Women's Health Weekly, December 7th, 2006
The company also reiterated plans for the U.S. launch of Caphosol in early 2007. Approved as a prescription medical device, Caphosolis a topical oral agent for the treatment of oral mucositis and dry mouth. Caphosol was acquired by Cytogen in October 2006 and represents its fourth approved oncology product in the United States.
Cytogen reported a net loss of $5.7 million, or $0.26 per basic and diluted share for the third quarter of 2006, compared to a net loss of $7.1 million, or $0.40 per basic and diluted share,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.